Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANOBEST panobinostat maintenance after allogeneic HSCT in high‑risk MDS/AML
2010-018699-26Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Goethe University Frankfurt. Primary endpoints: Maximum tolerated dose of panobinostat and Dose‑limiting toxicity of panobinostat. Started Aug 2010; status: completed.
02
Drugs
panobinostat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-018699-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018699-26.